MHB088C treatment for adults with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1/2, open-label, multicenter study using dose-escalation followed by dose-expansion and efficacy-expansion cohorts to characterize safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of single-agent MHB088C for injection. Eligible adults must have advanced or metastatic solid tumors, an ECOG performance status of 0–1, and an expected survival of at least three months; participants of childbearing potential must use reliable contraception and have a negative pregnancy test before dosing. The trial collects serial safety labs, adverse event data, drug PK and immunogenicity samples, and tumor response assessments to guide dose selection and expansion cohort activity signals. The lead sponsor is Qilu Pharmaceutical and the listed site is Beijing Cancer Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Agree to follow the experimental treatment plan and visit plan, join the group voluntarily, and sign a written informed consent form;
* Age ≥ 18 years old when signing the informed consent form;
* The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1;
* The expected survival time is at least 3 months;
* Eligible participants of childbearing potential must agree to take highly reliable contraceptive measures with their partners during the study and within at least 90 days after the last dose and agree not to retrieve, freeze or donate sperm or ova from screening to at least 3 months after the last dose of investigational drug; female participants of childbearing potential must have a negative results of blood pregnancy test before the first dose of investigational drug, and must be non-lactating.
* Understand study requirements, willing and able to comply with study and follow-up procedures.

Neoplasm-related criteria

* Phase Ia: Histologically or cytologically confirmed unresectable advanced or metastatic malignant solid tumors, that is progressed or intolerant with standard of care (SOC), or for which no SOC regimens are available.
* Phase Ib: Histologically or cytologically confirmed unresectable advanced or metastatic malignant solid tumors, that is relapsed or progressed following systemic treatment or no SOC is available;
* Phase II: Histologically or cytologically documented unresectable advanced or metastatic SCLC and previous progressed during or after platinum-contained chemotherapy and immune-checkpoint inhibitors (ICIs).

Exclusion Criteria:

* Has more than 2 primary malignancies before signing of Informed Consent Form.
* Has received anti-tumor treatment before the first dose of investigational product; Medication of traditional Chinese medicine before the first dose of investigational drug.
* Medication of other unmarketed investigational drugs or therapies before the first dose of investigational drug.
* Presence of unstable brain metastases and/or leptomeningeal carcinomatosis.
* Has adverse reactions from previous anti-tumor treatment that have not recovered to ≤ CTCAE 5.0 Grade 1;
* Has underwent major organ surgery or significant trauma before the first dose of investigational drug or requiring elective surgery during the study.
* Has vaccinated with attenuated live vaccines before the first dose of investigational drug.
* Has mucosal or internal bleeding for non-traumatic reason before the first dose of investigational drug.
* Has received treatment with systemic corticosteroids or other immunosuppressive agents before the first dose of investigational drug.
* Has pulmonary disease that severely impact pulmonary function.
* Has history of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, or current ILD/pneumonia, or suspected ILD/pneumonia that cannot be excluded by imaging examination at screening.

Where it's running

• Beijing Cancer Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Lin Shen, Ph.D
• Email: doctorshenlin@sina.cn
• Phone: 13911219511

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HLX316 first-in-human dose study in advanced/metastatic solid tumors

  A first-in-human, Phase 1 study tests HLX316 to see if it is safe and tolerable and to get early signs of how it behaves in the body and whether it shows any tumor-killing activity in adults with advanced solid tumors.

  Recruiting Phase 1 Shanghai Henlius Biotech · Chongqing and 4 other locations · NCT07541534

• HLX48 first-in-human safety study in advanced solid tumors

  This early-phase study tests HLX48 in adults with advanced/metastatic solid tumors to see if it is safe and how it behaves in the body.

  Recruiting at 2 sites Phase 1 Shanghai Henlius Biotech · North Ryde, New South Wales and 6 other locations · NCT07473726

• SYS6043 treatment for advanced or metastatic solid tumors

  We will test SYS6043, a B7‑H3‑targeted antibody‑drug conjugate, in adults with advanced or metastatic solid tumors who have progressed on or are intolerant of standard therapies.

  Recruiting Phase 1/2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Beijing, Beijing Municipality · NCT07415863

• HLX37 treatment for advanced or metastatic solid tumors, including non-small cell lung cancer

  This trial tests HLX37, given alone or with chemotherapy, to see if it is safe and how the body handles it in adults with advanced or metastatic solid tumors including non-small cell lung cancer.

  Recruiting at 2 sites Early Phase 1 Shanghai Henlius Biotech · Shanghai and 1 other locations · NCT07274813

• DB-1317 for selected advanced or metastatic solid tumors

  This study will try DB-1317, given every three weeks, in adults with advanced or metastatic solid tumors that have progressed after standard treatments.

  Recruiting at 14 sites Phase 1 DualityBio Inc. · Los Angeles, California and 13 other locations · NCT07141706

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.